Welcome to our dedicated page for Biora Therapeutics news (Ticker: $BIOR), a resource for investors and traders seeking the latest updates and insights on Biora Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biora Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biora Therapeutics's position in the market.
Rhea-AI Summary
Biora Therapeutics, Inc. secures $3 million in nondilutive capital through the monetization of legacy assets and $2.8 million in new capital from a convertible notes exchange with Context Capital. The company has significantly reduced its debt by over $80 million and attracted $19.8 million in new capital from institutional investors. Biora continues to optimize its capital structure and advance its therapeutic programs, with upcoming data release from the SAD portion of its phase 1 clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.72%
Tags
-
Rhea-AI Summary
Biora Therapeutics, Inc. completes SAD cohorts for BT-600 clinical study, with MAD dosing to start in March. The drug-device combination aims to treat ulcerative colitis by delivering tofacitinib directly to the colon for improved efficacy and reduced adverse events. Data from the SAD portion to be shared in March corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.67%
Tags
-
News
Rhea-AI Summary
Biora Therapeutics, Inc. (Nasdaq: BIOR) will participate in the Inflammatory Bowel Disease Symposium hosted virtually by Canaccord Genuity Capital Markets on February 28, 2024. Ariella Kelman, M.D., Chief Medical Officer, will participate in the panel titled 'The Next Evolutionary Steps in Addressing IBD.'
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.57%
Tags
Rhea-AI Summary
Biora Therapeutics, Inc. (Nasdaq: BIOR) will participate in a virtual fireside chat hosted by H.C. Wainwright & Co. to discuss the company’s delivery platforms addressing significant therapeutics indications, including its first ongoing clinical trial. The event is scheduled for January 29, 2024, at 11:00 AM Eastern / 8:00 AM Pacific. Adi Mohanty, CEO, Ariella Kelman, M.D., CMO, and Eric d’Esparbes, CFO, will be the speakers. A live webcast and replay of the fireside chat session will be available through the Investor Relations section of the Biora website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.86%
Tags
-
Rhea-AI Summary
Biora Therapeutics, Inc. (Nasdaq: BIOR) provided guidance on anticipated milestones in 2024, including clinical study results for NaviCap™ Targeted Oral Delivery Platform and progress on pharma partnerships for BioJet™ Systemic Oral Delivery Platform. The company completed a transformation in 2023, laying the foundation for significant value inflection. The phase 1 study for BT-600, a de-risking step in NaviCap™ platform development, is underway. The company expects to progress relationships with large pharma companies for the BioJet platform, potentially providing non-dilutive funding for further development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
-
Rhea-AI Summary
Biora Therapeutics, a biotech company listed on Nasdaq as BIOR, announced the initiation of its phase 1, first-in-human clinical study of BT-600, a drug-device combination program designed to deliver a unique, liquid formulation of tofacitinib to the colon for the potential treatment of moderate to severe ulcerative colitis. The study aims to evaluate the safety, pharmacokinetics, and pharmacodynamics of BT-600 in healthy adult volunteers, with expectations of increased colonic tissue drug levels and reduced systemic levels compared with conventional oral tofacitinib.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.19%
Tags
News
Rhea-AI Summary
Biora Therapeutics, Inc. (Nasdaq: BIOR) announced that its BioJet™ Systemic Oral Delivery Platform has exceeded performance targets in a preclinical study conducted in collaboration with AstraZeneca. The study demonstrated greater than 25% bioavailability compared to subcutaneous delivery, showcasing the platform's potential to deliver multi-milligram liquid doses similar to injection with minimal to no formulation changes. The company continues to generate promising results, enabling further development under the collaboration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
-
Rhea-AI Summary
Biora Therapeutics, Inc. (Nasdaq: BIOR) announces receipt of US Patent No. 11,857,669 for targeted delivery of JAK inhibitors to the gastrointestinal tract, a significant win for its BT-600 program and NaviCap™ targeted oral delivery platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
-
News
Rhea-AI Summary
Biora Therapeutics, Inc. (Nasdaq: BIOR) announced an agreement with institutional investors to reduce the company’s net debt by 60% through a convertible note exchange, bringing $16.7 million in new capital. The company has reduced its debt by $83 million in 2023, achieving a 75% overall reduction. The transaction demonstrates investor confidence in the company's innovative technologies and near-term catalysts for its NaviCap™ and BioJet™ platforms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.5%
Tags
Rhea-AI Summary
Biora Therapeutics, Inc. (Nasdaq: BIOR) announced a new research collaboration with a large pharmaceutical company to test the BioJet Systemic Oral Delivery Platform in animal models. The agreement provides funding to test the platform’s ability to achieve bioavailability through oral delivery of the collaborator’s molecules to the small intestine. The CEO, Adi Mohanty, highlighted the progress and recognition by others, stating that they are actively conducting studies with multiple collaborators and looking forward to performing studies with the big pharma collaborator in the first quarter. Biora's BioJet technology features strong patent protection and promises category-leading oral bioavailability for large molecules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.22%
Tags
Biora Therapeutics, Inc.
Nasdaq:BIOR
BIOR Rankings
BIOR Stock Data
26.18M
13.75M
7.91%
64.14%
4.42%
Medical Laboratories
Health Care and Social Assistance
United States of America
SAN DIEGO
About BIOR
progenity helps patients and their families prepare for life, with medically relevant health information starting before conception, through pregnancy, childhood, and adulthood. using our highly-complex molecular diagnostic testing, healthcare providers can access the most advanced genomic technology to guide patient care at critical life stages.